Miyauchi M, Nakayama E, Fujimoto K, Kawamoto I, Ide J
Sankyo Research Laboratories, Sankyo Co., Ltd., Tokyo, Japan.
Chem Pharm Bull (Tokyo). 1990 Jul;38(7):1906-10. doi: 10.1248/cpb.38.1906.
Oral delivery of 3-thiazoliomethyl cephalosporin 1 was attempted through a prodrug approach by applying thiamine chemistry. The 3-thiazoliomethyl group was modified to a ring-opened structure with no ionic charge, and the 4-carboxyl group was converted to pivaloyloxymethyl ester. Lipophilicity of the resulting derivatives (8-10) was suitable for passive absorption from the intestinal tract, and chemical stability in phosphate buffer solution (pH 6.86) was moderate. When administered orally to mice, these derivatives were mainly transformed to a novel 3-spiro cephalosporin 11, and desired reconversion to the 3-thiazoliomethyl cephalosporin was minor. Isomerization to delta 2-cephalosporin 14 was also observed. These results showed that the derivatives (8-10) tested in this study did not serve as orally active prodrugs of 3-thiazoliomethyl cephalosporin 1.
尝试通过应用硫胺化学的前药方法经口服递送3-噻唑基甲基头孢菌素1。3-噻唑基甲基被修饰为无离子电荷的开环结构,并且4-羧基被转化为新戊酰氧基甲酯。所得衍生物(8-10)的亲脂性适合于从肠道被动吸收,并且在磷酸盐缓冲溶液(pH 6.86)中的化学稳定性适中。当对小鼠口服给药时,这些衍生物主要转化为新型3-螺头孢菌素11,而期望再转化为3-噻唑基甲基头孢菌素的情况较少。还观察到向δ2-头孢菌素14的异构化。这些结果表明,本研究中测试的衍生物(8-10)不作为3-噻唑基甲基头孢菌素1的口服活性前药。